J Andrew Livingston

List of Publications by Citations

46 papers	555 citations	12 h-index	22 g-index
49 ext. papers	820 ext. citations	5.1 avg, IF	3.64 L-index

#	Paper	IF	Citations
46	Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 66-97	7.3	121
45	Immuno-genomic landscape of osteosarcoma. *Nature Communications*, **2020**, 11, 1008	17.4	77
44	3D tissue-engineered model of Ewing's sarcoma. *Advanced Drug Delivery Reviews*, **2014**, 79-80, 155-71	18.5	36
43	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. *Scientific Reports*, **2017**, 7, 11836	4.9	34
42	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. *Clinical Sarcoma Research*, **2017**, 7, 11	2.5	32
41	Chemotherapy for Bone Sarcoma in Adults. *Journal of Oncology Practice*, **2016**, 12, 208-16	3.1	30
40	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. *Oncologist*, **2017**, 22, 1271-1277	5.7	16
39	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. *Current Oncology Reports*, **2018**, 20, 37	6.3	14
38	Long-term survival among 5-year survivors of adolescent and young adult cancer. *Cancer*, **2020**, 126, 3708-3718	6.4	13
37	Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. *Oncotarget*, **2018**, 9, 1602-1616	3.3	13
36	MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. *Cancers*, **2019**, 11,	6.6	12
35	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. *Oncotarget*, **2016**, 7, 64421-64430	3.3	12
34	Analysis of HSP27 and the Autophagy Marker LC3B Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. *Molecular Cancer Therapeutics*, **2018**, 17, 1315-1323	6.1	11
33	Chemotherapy for bone sarcomas in adults: the MD anderson experience. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, e656-60	7.1	11
32	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. *Cancers*, **2020**, 12,	6.6	10
31	Disparities in Adolescent and Young Adult Sarcoma Survival: Analyses of the Texas Cancer Registry and the National SEER Data. *Journal of Adolescent and Young Adult Oncology*, **2018**, 7, 681-687	2.2	9
30	Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2019**, 42, 744-748	2.7	9

29	Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. *Pediatric Blood and Cancer*, **2017**, 64, e26318	3	8
28	Genomics and the Immune Landscape of Osteosarcoma. *Advances in Experimental Medicine and Biology*, **2020**, 1258, 21-36	3.6	8
27	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. *Cancers*, **2019**, 11,	6.6	7
26	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. *Cell Reports*, **2021**, 34, 108678	10.6	7
25	A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.. *Journal of Clinical Oncology*, **2020**, 38, 11509-11509	2.2	6
24	Pilot study of NKTR214 and nivolumab in patients with sarcomas.. *Journal of Clinical Oncology*, **2019**, 37, 11010-11010	2.2	5
23	Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association.. *Nature Communications*, **2022**, 13, 42	17.4	5
22	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. *Sarcoma*, **2020**, 2020, 8363986	3.1	5
21	Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. *Clinical Sarcoma Research*, **2020**, 10, 14	2.5	5
20	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. *Oncologist*, **2021**, 26, 250-260	5.7	5
19	Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. *Cancer Gene Therapy*, **2021**, 28, 1325-1338	5.4	5
18	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. *British Journal of Cancer*, **2020**, 122, 812-822	8.7	4
17	Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. *Journal of Adolescent and Young Adult Oncology*, **2021**, 10, 164-174	2.2	4
16	Extraskeletal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2019**, 42, 238-242	2.7	4
15	Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1717-1725	4	3
14	Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. *Journal of Adolescent and Young Adult Oncology*, **2019**, 8, 385-386	2.2	2
13	Emergency Department Visits by Adolescent and Young Adult Cancer Patients Compared with Pediatric Cancer Patients in the United States. *Journal of Adolescent and Young Adult Oncology*, **2018**, 7, 553-564	2.2	2
12	Improving Outcomes for Adolescents and Young Adults With Sarcoma: A Focus on Cancer Care Delivery. *Journal of Oncology Practice*, **2019**, 15, 253-254	3.1	2

11	A computational network approach to identify predictive biomarkers and therapeutic combinations for anti-PD-1 immunotherapy in cancer		1
10	Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.. *Journal of Clinical Oncology*, **2021**, 39, TPS11575-TPS11575	2.2	1
9	Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 1496-1504	4	1
8	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis.. *Cancer Epidemiology Biomarkers and Prevention*, **2022**, OF1-OF9	4	1
7	Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. *Oncologist*, **2022**, 27, 135-143	5.7	0
6	Hypofractionated radiation therapy for unresectable or metastatic sarcoma lesions. *Advances in Radiation Oncology*, **2022**, 100913	3.3	0
5	A phase I trial of aerosol gemcitabine for the treatment of patients with solid tumors and lung metastases.. *Journal of Clinical Oncology*, **2020**, 38, TPS3645-TPS3645	2.2	0
4	Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. *Cancer Epidemiology*, **2021**, 75, 102044	2.8	0
3	Factors impacting adolescent and young adult cancer patientsXdecision to pursue genetic counseling and testing.. *Supportive Care in Cancer*, **2022**, 1	3.9	0
2	Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.. *Journal of Clinical Oncology*, **2018**, 36, 10520-10520	2.2	
1	Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.. *Journal of Clinical Oncology*, **2018**, 36, 11522-11522	2.2	